- Home
- OSTX vs IKNA Comparison
OSTX vs IKNA Comparison
Compare OSTX & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSTX
- IKNA
- Stock Information
- Founded
- OSTX 2018
- IKNA 2016
- Country
- OSTX United States
- IKNA United States
- Employees
- OSTX N/A
- IKNA N/A
- Industry
- OSTX
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- OSTX
- IKNA Health Care
- Exchange
- OSTX NYSE
- IKNA Nasdaq
- Market Cap
- OSTX 86.5M
- IKNA 78.7M
- IPO Year
- OSTX 2024
- IKNA 2021
- Fundamental
- Price
- OSTX $3.16
- IKNA $1.70
- Analyst Decision
- OSTX Strong Buy
- IKNA Buy
- Analyst Count
- OSTX 1
- IKNA 2
- Target Price
- OSTX $21.00
- IKNA $3.00
- AVG Volume (30 Days)
- OSTX 61.1K
- IKNA 36.5K
- Earning Date
- OSTX 11-15-2024
- IKNA 11-07-2024
- Dividend Yield
- OSTX N/A
- IKNA N/A
- EPS Growth
- OSTX N/A
- IKNA N/A
- EPS
- OSTX N/A
- IKNA N/A
- Revenue
- OSTX N/A
- IKNA $1,844,000.00
- Revenue This Year
- OSTX N/A
- IKNA N/A
- Revenue Next Year
- OSTX $9,900.00
- IKNA N/A
- P/E Ratio
- OSTX N/A
- IKNA N/A
- Revenue Growth
- OSTX N/A
- IKNA N/A
- 52 Week Low
- OSTX $2.51
- IKNA $1.02
- 52 Week High
- OSTX $4.90
- IKNA $4.63
- Technical
- Relative Strength Index (RSI)
- OSTX N/A
- IKNA 50.42
- Support Level
- OSTX N/A
- IKNA $1.66
- Resistance Level
- OSTX N/A
- IKNA $1.76
- Average True Range (ATR)
- OSTX 0.00
- IKNA 0.05
- MACD
- OSTX 0.00
- IKNA -0.00
- Stochastic Oscillator
- OSTX 0.00
- IKNA 42.11
About OSTX OS THERAPIES INCORPORATED
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the significant need for new treatments in cancers of the bone in children and young adults.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.